We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.33% | 18.50 | 18.00 | 19.00 | 18.75 | 18.50 | 18.75 | 42,520 | 08:26:56 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -2.17 | 71.96M |
TIDMREDX
RNS Number : 8925O
Redx Pharma plc
24 August 2017
24 August 2017
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Permission granted for distribution to Unsecured Creditors
Redx, the drug discovery and development company, announces that Jason Baker and Miles Needham of FRP Advisory LLP, joint administrators of the Company and of its subsidiary, Redx Oncology Limited ("Oncology") (together, the "Companies") have been granted permission by the High Court to make a distribution to unsecured creditors of the Companies. The Joint Administrators will shortly be sending unsecured creditors notices of intended dividend, following which claims will be adjudicated and distributions made. All unsecured creditors will be paid in full (subject to adjudication). This is a significant step towards the anticipated rescue of the Companies as going concerns and the termination of the Administrations. A PDF copy of the Order is attached to this notice.
Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/8925O_-2017-8-24.pdf
For further information, please contact:
Redx Pharma Plc (in administration) Contact for the Joint Administrators: T: + 44 203 Chris French 005 4000 James Rossiter Cantor Fitzgerald Europe (Nomad & T: +44 20 Broker) 7894 7000 Phil Davies WG Partners LLP (Joint Broker) T: +44 20 3705 9330 Claes Spång/ Chris Lee/ David Wilson
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPIMPTMBJTMPR
(END) Dow Jones Newswires
August 24, 2017 04:42 ET (08:42 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions